Opinion

Video

Future Directions for Type 2 Inflammation Management

Author(s):

Reynold A. Panettieri Jr, MD

Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions.

  • Biologics are currently available for asthma management and being studied in COPD patients. Where do you envision the potential place of biologic therapies in the treatment algorithm for patients with type 2 inflammation-driven COPD?
    • How does the route of administration impact the treatment selection?
  • What emerging therapies for type 2 inflammation related to respiratory diseases are you most excited about? What are clinical trial data showing in terms of exacerbation and hospitalization rates, patient quality of life, and general disease management?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr John Mascarenhas
5 experts are featured in this series
2 experts in this video
4 experts in this video
5 experts are featured in this series
4 experts in this video
1 expert is featured in this series.
Related Content
Ovarian cancer | Image Credit: tashatuvango - stock.adobe.com
June 27th 2025

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Kristi Rosa
Mirvetuximab soravtansine continues to show efficacy and safety in the final analysis of the phase 2 PICCOLO study.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
3D illustration of ovarian cancer | Image Credit: Dr_Microbe - stock.adobe.com
June 25th 2025

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Chris Ryan
Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
Myasthenia gravis diagnosis | Image Credit: Maggie L. Shaw/sora.chatgpt.com
June 19th 2025

RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis

Abigail Lewis
Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.
Doctor speaking to a female patient with obesity | Image credit: Studio Romantic - stock.adobe.com
June 18th 2025

The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

Laura Joszt, MA
High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo